Colchicine to Prevent Long-Term Leg Problems After Deep Vein Thrombosis
Tests colchicine against placebo in adults with deep vein thrombosis in the leg.
Key facts
- Who runs it
- Universita' Degli Studi G. D'Annunzio Di Chieti
- Where
- Italy5 sites in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Study on the use of colchicine to reduce inflammation after deep vein thrombosis
- Status
- Not yet recruiting
- Phase
- Phase 2
- People taking part
- 122 people, planned
- Started
- 2 Feb 2026
- Expected to end
- 2 Aug 2028
- Type of study
- Interventional
- Record updated
- 8 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a first, sudden blood clot in a deep vein of the leg, at or above the knee. It tests whether colchicine 0.5 mg daily lowers the risk of post-thrombotic syndrome (long-term leg pain and swelling) compared with placebo.
- Age
- 18 years or older
- Sex
- All sexes
- Disease stage
- First, acute deep vein thrombosis with symptoms, in the popliteal vein (behind the knee) or higher in the leg, confirmed by a test.
- Earlier treatment
- People who recently (<30 days) or regularly used immunosuppressive drugs by mouth or vein (such as steroids, tumor necrosis factor-alpha blockers, cyclosporine) cannot join. People who need colchicine for another reason cannot join.
Main reasons for not taking part
- Known active cancer, HIV infection, or a recent (<30 days) or active infection
- Liver problems: ALT or AST >3x upper limit of normal, bilirubin >2x upper limit of normal, cirrhosis or severe liver disease
- Creatinine clearance <30 mL/min (poor kidney function)
- Pregnancy, breastfeeding, or women able to have children who will not use birth control
- Chronic diarrhoea, inflammatory bowel disease, blood disorders, colchicine allergy, or drugs that interact with colchicine such as erythromycin or clarithromycin
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- 18 years of age or older
- First, acute, symptomatic proximal (popliteal or more proximal vein) objectively-confirmed DVT of the lower extremity
- Written informed consent
Who cannot take part
- Participation in another interventional trial within the past 30 days or 5 half-lives of the study drug, whichever is longer
- Use of medications with known significant drug-to-drug interactions with colchicine including but not limited to erythromycin or clarithromycin
- Recent (<30 days) or chronic use of systemic (oral, intravenous) immunosuppressive drugs (including but not limited to steroids, tumor necrosis factor-alpha blockers, cyclosporine)
- Known active cancer
- Presence of HIV infection
- Hypersensitivity to the active substance or to any of the excipients
- History of an allergic reaction or significant sensitivity to colchicine
- Active or chronic diarrhoea, or documented inflammatory bowel disease (i.e., Crohn’s disease or ulcerative colitis), collagenous colitis/irritable bowel syndrome, or existing blood dyscrasias
- Known or suspected, recent (<30 days) or active infections (acute or chronic)
- History of cirrhosis, chronic active hepatitis, or severe liver disease
- Any of the following as measured within the past 1-3 months or at screening: alanine or aspartate aminotransferase >3x upper limit of normal (ULN); total bilirubin >2x ULN; creatinine clearance, calculated using Cockcroft-Gault formula, <30 mL/min
- Any contraindication to colchicine as per summary of product characteristics (SmPC)
- Unwilling to provide consent
- Pregnancy, breastfeeding or may be considering pregnancy during the study period or women of childbearing potential unwilling to use appropriate contraception during sex
- Requirement of colchicine for other indications
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
To evaluate the safety and efficacy of low-dose colchicine 0.5 mg versus placebo once daily in reducing the risk of Post-thrombotic syndrome (PTS) in patients with proximal lower-extremity deep vein thrombosis (DVT).
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Colchicine to Quench the Inflammatory Response after Deep Vein Thrombosis: The CONQUER-DVT Randomized Controlled Trial
- Plain-language title
- Colchicine to Prevent Long-Term Leg Problems After Deep Vein ThrombosisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Record updated
- 8 June 2026